BETRF
BetterLife Pharma Inc.
OTC Markets OTCQBUSDEQUITY
Healthcare
DELAYED
Neutral
-2/100
Last price
0.19
▼ 0.01 (3.55%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
0.20
Day high
0.21
Day low
0.19
Volume
67.50K
Market cap
$117.42M
P/E (TTM)
—
52W range
0.03 – 0.33
Trailing performance
Returnvs SPY
1W
-8.21%
-10.2%
1M
-14.41%
-15.6%
3M
+39.71%
+35.2%
6M
+272.55%
+254.4%
YTD
+493.75%
+479.5%
1Y
+280.00%
+263.6%
3Y
+265.38%
+183.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BETRF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
55.14M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 25, 26 | Duncan (Charles) Director of Issuer |
— | 0 | — | Direct |
| Aug 5, 26 | Sangha (Steven) 10% Security Holder of Issuer |
— | 1.00M | — | Direct |
| Jun 23, 26 | Doroudian (Ahmad) Director of Issuer |
BUY | 50.00K | $3.00K | Direct |
| Jun 22, 26 | Doroudian (Ahmad) Director of Issuer |
BUY | 50.00K | $2.50K | Direct |
| Jun 19, 26 | Drysdale (Douglas Lee) Director of Issuer |
— | 100.00K | — | Direct |
| Jun 5, 26 | Sangha (Steven) 10% Security Holder of Issuer |
BUY | 52.00K | $2.24K | Direct |
| Jun 4, 26 | Sangha (Steven) 10% Security Holder of Issuer |
BUY | 229.00K | $9.85K | Direct |
| Jun 1, 26 | Sangha (Steven) 10% Security Holder of Issuer |
BUY | 121.00K | $5.20K | Direct |
| May 29, 26 | Sangha (Steven) 10% Security Holder of Issuer |
BUY | 126.00K | $5.42K | Direct |
| May 28, 26 | Sangha (Steven) 10% Security Holder of Issuer |
BUY | 127.00K | $5.59K | Direct |
| May 27, 26 | Sangha (Steven) 10% Security Holder of Issuer |
BUY | 327.00K | $14.06K | Direct |
| May 27, 26 | Sangha (Steven) 10% Security Holder of Issuer |
BUY | 2.00K | $86 | Direct |
| May 26, 26 | Sangha (Steven) 10% Security Holder of Issuer |
BUY | 15.00K | $645 | Direct |
| May 25, 26 | Sangha (Steven) 10% Security Holder of Issuer |
BUY | 4.00K | $172 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Doroudian (Ahmad) |
Director of Issuer | 15.63M | Acquisition or disposition in the public market |
Drysdale (Douglas Lee) |
Director of Issuer | 1.61M | Acquisition or disposition under a prospectus exemption |
Duncan (Charles) |
Director of Issuer | 0 | Opening Balance-Initial SEDI Report |
Pullen (Ralph Anthony) |
Director of Issuer | — | Acquisition or disposition in the public market |
Sangha (Steven) |
10% Security Holder of Issuer | 26.51M | Exercise of warrants |
Fundamentals
Market cap$117.42M
Enterprise value$122.44M
Revenue (TTM)—
Gross profit—
EBITDA—
Net income$-3.48M
EPS (TTM)$-0.02
Free cash flow$-473.77K
Total cash$973.59K
Total debt$2.89M
Book value / share$-0.04
Shares outstanding618.01M
Float507.41M
Short % of float—
Dividend yield0.00%
Beta (5Y)0.22
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets-140.79%
Debt / equity—
Current ratio0.21
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | — | — |
| Research & development | $85.67K | $424.34K | $570.95K | $2.68M | — | -79.8% |
| Selling, general & admin | $1.72M | $4.30M | $2.64M | $6.56M | — | -59.9% |
| Total operating expense | $1.81M | $4.72M | $3.21M | $9.26M | — | -61.7% |
| Operating income | -$1.81M | -$4.72M | -$3.21M | -$9.26M | — | +61.7% |
| Net interest income | -$262.37K | $439.36K | -$84.95K | -$91.09K | — | -159.7% |
| Pre-tax income | -$1.51M | -$3.62M | -$2.90M | -$9.37M | — | +58.2% |
| Tax provision | — | — | $0 | $0 | $166.67K | — |
| Net income | -$1.50M | -$3.52M | -$2.89M | -$9.02M | — | +57.5% |
| Net income to common | -$1.50M | -$3.52M | -$2.89M | -$9.02M | — | +57.5% |
| Basic EPS | -0.01 | -0.03 | -0.03 | -0.10 | — | +66.7% |
| Diluted EPS | -0.01 | -0.03 | -0.03 | -0.10 | — | +66.7% |
| EBIT | -$1.28M | -$3.30M | -$2.85M | -$9.31M | — | +61.2% |
| EBITDA | -$1.28M | -$3.30M | -$2.85M | -$9.29M | — | +61.2% |
| Basic shares | 145.88M | 123.87M | 109.29M | 86.56M | — | +17.8% |
| Diluted shares | 145.88M | 123.87M | 109.29M | 86.56M | — | +17.8% |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $12.57K | $8.18K | $37.38K | $8.31K | — | +53.7% |
| Cash & short-term investments | $12.57K | $8.18K | $37.38K | $8.31K | — | +53.7% |
| Accounts receivable | $2.86K | $11.64K | $39.54K | $17.20K | — | -75.5% |
| Total current assets | $219.90K | $224.96K | $324.75K | $74.73K | — | -2.2% |
| Property, plant & equipment | — | $0 | $0 | $0 | $18.43K | — |
| Goodwill & intangibles | — | — | — | $0 | $0 | — |
| Total assets | $219.90K | $224.96K | $324.75K | $74.73K | — | -2.2% |
| Total current liabilities | $6.68M | $7.54M | $7.35M | $7.15M | — | -11.4% |
| Current debt | $785.03K | $870.61K | $245.23K | $80.00K | — | -9.8% |
| Long-term debt | $27.17K | $49.12K | $82.50K | — | $34.56K | -44.7% |
| Total debt | $1.23M | $1.30M | $1.47M | $1.19M | — | -5.9% |
| Total liabilities | $6.71M | $7.59M | $8.02M | $7.61M | — | -11.6% |
| Retained earnings | -$120.09M | -$118.60M | -$115.08M | -$112.19M | — | -1.3% |
| Shareholder equity | -$9.78M | -$10.68M | -$10.81M | -$10.73M | — | +8.4% |
| Working capital | -$6.46M | -$7.31M | -$7.02M | -$7.07M | — | +11.7% |
| Net tangible assets | -$9.78M | -$10.68M | -$10.81M | -$10.73M | — | +8.4% |
| Shares issued | 151.90M | 129.57M | 115.83M | 90.10M | — | +17.2% |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$1.51M | -$3.62M | -$2.90M | -$9.37M | — | +58.2% |
| Depreciation & amortisation | — | $0 | $0 | $18.43K | $18.44K | — |
| Stock-based compensation | $169.75K | $2.05M | $500.26K | $951.07K | — | -91.7% |
| Change in working capital | $1.21M | $752.87K | $321.61K | $3.43M | — | +61.1% |
| Operating cash flow | -$625.46K | -$2.02M | -$2.47M | -$1.50M | — | +69.1% |
| Investing cash flow | — | — | — | $0 | $0 | — |
| Financing cash flow | $629.26K | $1.99M | $2.50M | $1.34M | — | -68.4% |
| Free cash flow | -$625.46K | -$2.02M | -$2.47M | -$1.50M | — | +69.1% |
| End cash position | $12.57K | $8.18K | $37.38K | $8.31K | — | +53.7% |
| Line item | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $21.50K | $58.49K | $11.98K | $1.58K | $13.62K | -63.2% |
| Selling, general & admin | $539.89K | $378.51K | $377.24K | $510.05K | $457.12K | +42.6% |
| Total operating expense | $561.39K | $437.01K | $389.21K | $511.63K | $470.75K | +28.5% |
| Operating income | -$561.39K | -$437.01K | -$389.21K | -$511.63K | -$470.75K | -28.5% |
| Net interest income | -$29.80K | -$101.92K | -$35.76K | -$47.58K | -$77.10K | +70.8% |
| Pre-tax income | -$612.62K | -$381.62K | -$420.13K | -$504.11K | -$207.05K | -60.5% |
| Net income | -$609.26K | -$380.55K | -$409.01K | -$494.48K | -$211.45K | -60.1% |
| Net income to common | -$609.26K | -$380.55K | -$409.01K | -$494.48K | -$211.45K | -60.1% |
| Basic EPS | 0.00 | — | 0.00 | -0.00 | 0.00 | — |
| Diluted EPS | 0.00 | — | 0.00 | -0.00 | 0.00 | — |
| EBIT | -$582.83K | -$310.13K | -$384.37K | -$456.53K | -$129.95K | -87.9% |
| EBITDA | -$582.83K | -$310.13K | -$384.37K | -$456.53K | -$129.95K | -87.9% |
| Basic shares | 154.43M | — | 151.86M | 149.71M | 130.11M | — |
| Diluted shares | 154.43M | — | 151.86M | 149.71M | 130.11M | — |
| Line item | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $28.58K | $12.57K | $7.96K | $22.16K | $19.00K | — | +127.3% |
| Cash & short-term investments | $28.58K | $12.57K | $7.96K | $22.16K | $19.00K | — | +127.3% |
| Accounts receivable | $7.97K | $2.86K | $11.61K | $9.20K | $8.20K | — | +179.2% |
| Total current assets | $242.43K | $219.90K | $291.13K | $229.34K | $231.86K | — | +10.2% |
| Property, plant & equipment | — | — | — | — | — | $0 | — |
| Total assets | $242.43K | $219.90K | $291.13K | $229.34K | $231.86K | — | +10.2% |
| Total current liabilities | $6.65M | $6.68M | $6.36M | $5.99M | $6.26M | — | -0.4% |
| Current debt | $589.83K | $785.03K | $563.68K | $589.73K | $870.43K | — | -24.9% |
| Long-term debt | $27.68K | $27.17K | $95.95K | $53.61K | $51.28K | — | +1.9% |
| Total debt | $1.04M | $1.23M | $1.04M | $1.03M | $1.30M | — | -15.4% |
| Total liabilities | $6.68M | $6.71M | $6.46M | $6.04M | $6.32M | — | -0.4% |
| Retained earnings | -$120.70M | -$120.09M | -$119.71M | -$119.30M | -$118.81M | — | -0.5% |
| Shareholder equity | -$9.73M | -$9.78M | -$9.46M | -$9.12M | -$9.40M | — | +0.6% |
| Working capital | -$6.41M | -$6.46M | -$6.07M | -$5.76M | -$6.03M | — | +0.8% |
| Net tangible assets | -$9.73M | -$9.78M | -$9.46M | -$9.12M | -$9.40M | — | +0.6% |
| Shares issued | 161.79M | 151.90M | 151.90M | 151.84M | 145.37M | — | +6.5% |
| Line item | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$612.62K | -$381.62K | -$419.65K | -$504.59K | -$207.05K | -60.5% |
| Stock-based compensation | $152.93K | $9.24K | $57.68K | $38.69K | $64.14K | +1,555.1% |
| Change in working capital | $168.12K | $50.29K | $340.97K | $397.36K | $424.06K | +234.3% |
| Operating cash flow | -$239.23K | -$427.03K | -$11.87K | -$172.31K | -$14.24K | +44.0% |
| Financing cash flow | $255.06K | $431.02K | -$1.76K | $175.00K | $25.00K | -40.8% |
| Free cash flow | -$239.23K | -$427.03K | -$11.87K | -$172.31K | -$14.24K | +44.0% |
| End cash position | $28.58K | $12.57K | $7.96K | $22.16K | $19.00K | +127.3% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders8.92%
Held by institutions8.97%
Institutions holding1
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.22
-12.24% from price
SMA 20
0.23
-17.32% from price
SMA 50
0.23
-16.82% from price
SMA 100
0.16
+19.98% from price
SMA 200
0.10
+87.48% from price
EMA 12
0.21
-11.15% from price
EMA 26
0.22
-14.15% from price
EMA 50
0.21
-9.64% from price
RSI (14)
41.6
Neutral
MACD (12,26,9)
-0.01
Hist -0.01
ATR (14)
0.02
12.18% of price
Realised vol 30D
142.8%
Annualised
Bollinger upper
0.28
20, 2σ
Bollinger lower
0.18
20, 2σ
50 / 200 cross
Golden
0.23 vs 0.10
Trend bias
Above 200
+87.48%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.05
Less volatile than market
Correlation to SPY
0.00
Largely independent
Realised vol 30D
142.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-47.3%
Peak to trough
Max drawdown 5Y
-88.4%
Peak to trough
ATR 14
0.02
12.18% of price
Beta (reported)
0.22
5Y monthly, from filing
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateJun 26, 2020
Last split1:10
Split dateJun 26, 2020
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-09-30
Corporate Changes & Voting Matters
6-K · 2026-09-15
Corporate Changes & Voting Matters
6-K · 2026-09-11
Corporate Changes & Voting Matters
6-K · 2026-08-24
Corporate Changes & Voting Matters
6-K · 2026-08-05
Corporate Changes & Voting Matters
6-K · 2026-06-26
Corporate Changes & Voting Matters
6-K · 2026-06-25
Periodic Financial Reports
20-F · 2026-06-01
Headlines
BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting
TMX Newsfile · 8d ago
BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
TMX Newsfile · 20d ago
BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
TMX Newsfile · 26d ago
BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee
TMX Newsfile · 37d ago
BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
TMX Newsfile · 40d ago
BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
TMX Newsfile · 44d ago
BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer
TMX Newsfile · 49d ago
BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism
TMX Newsfile · 86d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.